% | $
Quotes you view appear here for quick access.

EDAP TMS SA Message Board

hofno2003 4 posts  |  Last Activity: Sep 23, 2016 3:19 AM Member since: Jul 7, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    If approved, what is your exit price?

    by mike59sc Sep 23, 2016 2:03 AM
    hofno2003 hofno2003 Sep 23, 2016 3:19 AM Flag

    I think my expectations depend on the ADF label of Remoxy. If PTIE gets a label to deter all three main routes of abuse (oral, injection, snorting) - then the Remoxy value proposition is superior to most other approved ADFs and my expectation for the market potential is somewhere at $300+ million (15+% of ER opioid market). This way I expect and derive a fair company value for a buyout of 3 x $300+ million = $900+ million = $900 million / 46 million shares = $20+ per share.

    Sentiment: Strong Buy

  • Reply to

    Jim FIckenScher resigning

    by foogie88 Aug 11, 2016 7:24 AM
    hofno2003 hofno2003 Aug 12, 2016 3:07 AM Flag

    Why to leave a company? Perhaps because a buyout is prepared behind the curtain.

    Sentiment: Strong Buy

  • Reply to


    by michaelrodman722 Jul 28, 2016 9:11 AM
    hofno2003 hofno2003 Jul 28, 2016 11:01 AM Flag

    Would be good if we had a clue about the driving forces for this strong upmove.

  • Reply to

    • How to get the old message board format back:

    by hofno2003 Jul 14, 2016 11:18 AM
    hofno2003 hofno2003 Jul 25, 2016 2:15 AM Flag

    I sold CTSO in order to shift the money to EDT.TO - because EDT.TO has an earlier key milestone concerning a final pivotal phase 3 bacterial induced sepsis trial. If my strategy works (and, yes, there is some risk that EDT.TO will fail to prove a survival benefit with it's device) - then I will again divest EDT.TO and invest the money in CTSO for the long run. I am a full believer in CTSO's technology - and the weekly case reports clearly demonstrate that CTSO's device will provide an outstanding survival benefit - but we need a controled pivotal study with an survival adavante endpoint in order to get a final US approval. Nevertheless the revenue at CTSO will continue to climb outside US ......

2.72-0.10(-3.55%)Oct 21 3:59 PMEDT